Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad(MYGN) Newsfilter·2024-02-01 14:25SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah. Myriad's Precise Tumor Test, which was also offered by IPG as TheraMap®: Solid Tumor, analyzes ...